Friedreich Ataxia (FA) is a rare hereditary neurodegenerative disease characterized by progressive loss of coordination (ataxia), muscle weakness, and heart disease. It is the most common inherited ataxia, affecting approximately 1 in 40,000 people in the United States.[1] The condition primarily affects the nervous system and heart, leading to significant disability over time.
Friedreich Ataxia is an autosomal recessive genetic disorder caused by mutations in the FXN gene (also known as the frataxin gene), which provides instructions for producing the protein frataxin. Frataxin is essential for normal mitochondrial function, particularly in tissues that require high energy output such as the heart, spinal cord, and cerebellum.[2]
The disease was first described by Nikolaus Friedreich, a German physician, in 1863. It remains one of the most common hereditary ataxias worldwide and disproportionately affects individuals of European, Middle Eastern, South Asian, and North African ancestry.[1]
Friedreich Ataxia is caused by a GAA trinucleotide repeat expansion in the FXN gene located on chromosome 9q13.[3] Normal individuals have 5-33 GAA repeats, while affected individuals have 66 to over 1,000 repeats.[1] This expansion leads to reduced expression of frataxin protein through a mechanism involving chromatin condensation and transcriptional repression.
Frataxin is a mitochondrial protein critical for iron-sulfur cluster (Fe-S) assembly, a process essential for the function of numerous enzymes involved in energy production, DNA repair, and oxidative stress response.[4] The deficiency of frataxin leads to:
The length of the GAA repeat expansion correlates with disease severity and age of onset. Individuals with fewer than 300 repeats typically have later onset (after age 25), while those with more than 1,000 repeats often experience earlier onset and more severe disease progression.[5]
The hallmark symptom of Friedreich Ataxia is progressive ataxia—Loss of coordination affecting gait, balance, and fine motor control. Clinical features include:[6]
Neurological Manifestations
Cardiac Involvement
Systemic Manifestations
Diagnosis is based on clinical examination findings including:[7]
Confirmatory genetic testing for GAA repeat expansion in the FXN gene gene is the gold standard for diagnosis. Testing can also identify carriers (heterozygotes) with 34-66 repeats.[1]
In February 2023, the U.S. Food and Drug Administration approved omaveloxolone (marketed as Skyclarys) for the treatment of Friedreich Ataxia in adults and adolescents aged 16 years and older.[8] This is the first FDA-approved therapy for the disease.
Omaveloxolone is a Nrf2 activator that works by reducing oxidative stress and improving mitochondrial function. Clinical trials demonstrated improvement in neurological function scores compared to placebo.[9]
Several therapeutic approaches are under investigation:[10]
The disease typically progresses over 10-20 years, with most individuals requiring wheelchair assistance approximately 10-15 years after symptom onset.[6] Life expectancy is reduced, primarily due to cardiac complications. However, with modern cardiac care and the new FDA-approved therapy, outcomes are improving.
Late-onset forms (LOFA and VLOFA) generally have a slower rate of progression and better functional outcomes compared to classic Friedreich Ataxia.[5]
Multiple clinical trials are ongoing to develop new treatments for Friedreich Ataxia. Research focuses on:
Patients are encouraged to consult ClinicalTrials.gov for information about enrolling in clinical trials.
The study of Friedreich Ataxia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
MedlinePlus. "Friedreich Ataxia." Genetics Home Reference. https://medlineplus.gov/genetics/condition/friedreich-ataxia/
Pandolfo, M. "Friedreich Ataxia: The Clinical Spectrum." Journal of Neurology 246 (2009): 67-71.
Campuzano, V., et al. "Friedreich Ataxia: Autosomal Recessive Disease Caused by an Intronic GAA Triplet Repeat Expansion." Science 271 (1996): 1423-1427.
Benoit, P., et al. "Frataxin and Mitochondrial Iron-Sulfur Cluster Assembly." Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1793 (2009): 178-185.
Reetz, K., et al. "Genotype Characters in Patients with Late-Onset Friedreich Ataxia." Neurology 85 (2015): 1-10.
P不如e, W., et al. "Friedreich Ataxia." Lancet Neurology 14 (2015): 1121-1134.
Lynch, D.R., et al. "Diagnostic Criteria for Friedreich Ataxia." Pediatric Neurology 26 (2002): 61-63.
U.S. Food and Drug Administration. "FDA Approves First Treatment for Friedreich Ataxia." February 2023. https://www.fda.gov
Lynch, D.R., et al. "Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study)." Annals of Neurology 91 (2022): 347-358.
Stella, A., et al. "Therapeutic Approaches for Friedreich Ataxia." Journal of Clinical Medicine 11 (2022): 3240.